BioCancell reveals pre-clinical results in pancreatic cancer treatment

Treatment arrests tumor growth and prevents metastases

San Diego, CA — In a lecture to the American Society of Investigative Pathology (ASIP), BioCancell Therapeutics CSO Prof. Avraham Hochberg today announced new pre-clinical results in the treatment of pancreatic cancer.

A group of hamsters was treated with BC-819 and compared to a control group. Results included:

* No metastases were found in the treated group, while 75% of the animals in the control group presented metastases.

* Tumor growth progression (TGP) was significantly reduced in the treated group as compared with the control group.

* Primary pancreatic tumor volume in the treated group was significantly reduced (50%) as compared with those in the control group.

It is expected that these results, together with previous cell line and mouse trials, as well as encouraging toxicity results to be received, should form a sufficient basis for coordination with the FDA to begin a Phase I clinical trial of BC-819 for pancreatic cancer, in conjunction with the Massey Cancer Center of Virginia State University.

In addition, Prof. Hochberg displayed new results proving a connection between the H19 gene (an integral part of BioCancell’s drugs) and the P53 gene (one of the central and most important genes in human cancers).




BC-819 is BioCancell’s leading product. It is a plasmid in which H19 regulatory sequences drive the expression of Diphtheria Toxin A gene. Besides the treatment of bladder cancer, BC-819 is in the process of being evaluated as treatment for liver, pancreatic and ovarian cancer and has shown efficacy in pre-clinical studies as well as in compassionate use.

Pancreatic Cancer

A patient diagnosed with pancreatic cancer today has a 10-15% chance of surviving one year, which is the lowest survival rate of any common cancer type. A quarter of a million patients are diagnosed with this disease each year, and while it is the eleventh-most common cancer, it is the fourth-largest killer.

Some $2.6 billion is spent in the U.S. on treating pancreatic cancer annually.

About BioCancell

BioCancell Therapeutics Inc. is a biopharmaceuticals corporation specializing in the development of Patient-Oriented, Targeted Therapy for the treatment of numerous types of cancer. The Company’s proprietary technology constitutes a novel paradigm for the targeted destruction of cancer cells, with no effect on normal surrounding tissue and no observed side effects, allowing for long-term, safe treatment and prevention of cancer.


BioCancell was co-founded in 2004 by Professor Avraham Hochberg, Professor of Molecular Biology at the Hebrew University of Jerusalem, based on technology developed by him over the past 15 years.

In 2006, BioCancell successfully completed a private round of funding and an initial public offering totalling $8.5 million. Its securities are traded on the Tel Aviv Stock Exchange, with the major stockholders being Clal Biotechnology Industries (a member of the IDB group of companies), and Prof. Hochberg.


This press release contains “forward-looking” statements, including statements with respect to the further development and potential safety and efficacy of BC-819, in the treatment of superficial bladder cancer and BioCancell’s development strategy. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. There are a number of important factors that could cause the results of BioCancell to differ materially from those indicated by these forward-looking statements, including, among others, the risk that the U.S. Food and Drug Administration may require changes to the protocols and informed consents for clinical trials of BC-819, which changes may have a material adverse effect on the timing of, and BioCancell’s ability to conduct, those clinical trials, risks related to the clinical advancement of its BC-819 plasmid, including, but not limited, to the risk that clinical trials for this product candidate may not demonstrate safety and efficacy sufficient to obtain the requisite regulatory approvals or to result in a marketable product and risks related to the potential for others to develop products containing or based on BC-819. BioCancell does not undertake any obligation to update forward-looking statements.

Comments are closed.